Treatment with Methotrexate and Low-dose Corticosteroids in Sarcoidosis Patients with Cardiac Lesions
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the effectiveness of combination therapy consisting of low-dose corticosteroids with weekly methotrexate in patients with cardiac sarcoidosis in whom long-term therapy is required. Combination therapy was selected because long-term standard corticosteroid therapy tends to result in various adverse effects and the steroid-sparing effects of methotrexate have been reported. METHODS: This study was a small open-label study comparing long-term functional changes between patients who received combination therapy (5-15 mg/day of prednisolone and 6 mg/week of methotrexate) and patients who received corticosteroids alone. The comparative analysis was based on the following therapeutic indexes: ejection fraction (EF), left ventricular end-diastolic diameter (LVDd) on echocardiography, serum N-terminal fragment pro-brain natriuretic peptide (NT-proBNP) and cardiothoracic ratio (CTR) on plain chest radiographs. PATIENTS: Seventeen patients with cardiac sarcoidosis were examined in the sarcoidosis clinic. Cardiac sarcoidosis was diagnosed based on the Japanese diagnostic guidelines published in 2006. RESULTS: The EF was significantly stabilized in the combination therapy group but not in the corticosteroids alone group at three years after the first treatment. The CTR and NT-proBNP levels were significantly stabilized in the combination therapy group compared with those observed in the corticosteroids alone group at both three and five years after the first treatment. The LVDd values tended to be stable in the combination therapy group compared with those observed in the corticosteroids alone group. The combination therapy was associated with few adverse effects. CONCLUSION: Weekly methotrexate therapy with daily small doses of corticosteroids stabilized the EF, CTR and NT-proBNP levels in the serum without eliciting adverse effects longitudinally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis
BAUGHMAN, R. P., TEIRSTEIN, A. S., JUDSON, M. A., ROSSMAN, M. D., YEAGER, H., BRESNITZ, E. A., DePALO, L., HUNNINGHAKE, G., IANNUZZI, M. C., JOHNS, C. J., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.10.2104046 · Cited by 1,808
Cited by
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis ― Digest Version ―
Terasaki, F., Azuma, A., Anzai, T., Ishizaka, N., Ishida, Y., Isobe, M., Inomata, T., Ishibashi-Ueda, H., Eishi, Y., Kitakaze, M., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0508 · Cited by 479
Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis
Ungprasert, P., Ryu, J. H., & Matteson, E. L. (2019) · Mayo Clinic Proceedings: Innovations, Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.04.006 · Cited by 297
Inflammatory Cardiomyopathic Syndromes
Trachtenberg, B. H., & Hare, J. M. (2017) · Circulation Research · doi:10.1161/circresaha.117.310221 · Cited by 289
Cardiac sarcoidosis: state-of-the-art review
Kouranos, V., & Sharma, R. (2021) · Heart · doi:10.1136/heartjnl-2019-316442 · Cited by 259
Metadata
- Authors
- Nagai, S., Yokomatsu, T., Tanizawa, K., Ikezoe, K., Handa, T., Ito, Y., Ogino, S., & Izumi, T.
- Venue
- Internal Medicine
- Published
- 2014
- Volume
- 53
- Issue
- 5
- Pages
- 427-433
- ISSN
- 0918-2918 (ISSN-L)
- 1349-7235
- OpenAlex
- W2094871419
- Cited by
- 122
- References
- 1
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with Methotrexate and Low-dose Corticosteroids in Sarcoidosis Patients with Cardiac Lesions. https://app.cochat.ai/papers/10.2169/internalmedicine.53.0794
- The paper
- Nagai, S., Yokomatsu, T., Tanizawa, K., Ikezoe, K., Handa, T., Ito, Y., Ogino, S., & Izumi, T. (2014). Treatment with Methotrexate and Low-dose Corticosteroids in Sarcoidosis Patients with Cardiac Lesions. Internal Medicine. https://doi.org/10.2169/internalmedicine.53.0794
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.